Inorganic Chemistry
Article
TOF, negative mode, terthiophene, m/z): 1348.23, C103H28N6 ([M +
e]−) requires 1348.24. Anal. Calcd for C103H28N6·4H2O·5(hexane): C,
86.24; H, 5.77; N, 4.54. Found: C, 86.11; H, 5.48; N, 4.44.
(MeCN)3](PF6)2 (6.4 mg, 8.5 μmol) and 8a (9.4 mg, 8.4 μmol)
were reacted to yield a dark red solid (6 mg, 3.4 μmol, 41%). 1H NMR
3
(400 MHz, CD3CN, ppm): δ 9.02 (s, 2H, HD3), 8.75 (d, J = 8.2 Hz,
3
2H, HB3), 8.69−8.57 (m, 4H, HE2, HC3), 8.48 (d, J = 8.1 Hz, 2H,
N-Methyl-2-(4-[2,2′:6′, 2″]terpyridin-4′-ylphenyl)-
pyrrolidinofullerene (10a). A mixture of (4-formylphenyl)-2,2′:6′,2″-
terpyridine (9a; 33 mg, 0.098 mmol), N-methylglycine (87 mg, 0.978
mmol), and C60 (282 mg, 0.391 mmol) in deaerated, anhydrous
toluene (200 mL) was stirred at 120 °C for 24 h under a nitrogen
atmosphere. After the mixture was cooled to room temperature, the
solvent was evaporated. The crude product was purified by column
chromatography (neutral alumina, toluene then chloroform), and slow
vapor diffusion of diethyl ether into a concentrated solution yielded a
3
3
HA3), 8.41 (t, J = 8.1 Hz, 1H, HB4), 8.35 (d, J = 7.2 Hz, 4H, HG2,
HE3), 8.00−7.80 (m, 4H, HC4, HA4), 7.61−7.48 (m, 2H, HG3), 7.49−
7.39 (m, 1H, HG4), 7.38−7.30 (m, 4H, HA6, HC6), 7.21−7.01 (m, 4H,
HC5, HA5). 13C NMR (100 MHz, CD3CN, ppm): δ 159.05, 159.00,
156.47, 156.28, 153.58, 153.22, 149.57, 149.52, 148.25, 146.94, 146.80,
146.20, 145.72, 145.70, 145.61, 145.36, 145.27, 144.83, 143.96, 143.89,
143.17, 143.08, 142.46, 141.83, 139.77, 139.10, 139.01, 138.84, 138.69,
137.71, 136.89, 133.19, 132.11, 130.11, 129.73, 129.38, 128.52, 128.47,
125.49, 124.76, 122.70, 80.14, 58.87. HRMS (ESI-TOF, m/z):
726.0829, C103H30N6Ru ([M − 2PF6]2+) requires 726.0785.
1
brown solid (26.5 mg, 0.024 mmol, 25%). Mp: >360 °C. H NMR
3
(300 MHz, CDCl3, ppm): δ 8.74 (s, 2H, HD3), 8.72 (d, J = 4.8 Hz,
3
2H, HC6), 8.67 (d, J = 7.9 Hz, 2H, HC3), 8.00−7.93 (m, 4H, HE2,
[Ru(tpy)(8b)](PF6)2 (1b). According to the general procedure for
heteroleptic ruthenium bis(terpyridine) complexes, [Ru(tpy)-
(MeCN)3](PF6)2 (6.4 mg, 8.5 μmol) and 8b (9 mg, 6.1 μmol)
were reacted to yield a dark red solid (4 mg, 1.9 μmol, 31%). 1H NMR
HE3), 7.87 (td, 3J = 7.8 Hz, 4J = 1.7 Hz, 2H, HC4), 7.35 (ddd, 3J = 7.5
Hz, 3J = 4.8 Hz, 4J = 1.1 Hz, 2H, HC5), 5.02 (d, 2J = 9.2 Hz, 1H, HH5),
5.02 (s, 1H, HH2), 4.30 (d, 2J = 9.5 Hz, 1H, HH5), 2.85 (s, 3H, NCH3).
MS (MALDI-TOF, negative mode, terthiophene, m/z): 1083.26,
C84H19N4 ([M − H]−) requires 1083.16. Anal. Calcd for C84H20N4·
6H2O: C, 84.56; H, 2.70; N, 4.70. Found: C, 84.26; H, 2.44; N, 5.40.
N-Methyl-2-(2,5-Bis(octyloxy)-4-(4-[2,2′:6′,2″]terpyridin-4′-
ylphenylethynyl))pyrrolidinofullerene (10b). A mixture of 2,5-bis-
(octyloxy)-4-(4-[2,2′:6′,2″]-terpyridin-4′-ylphenylethynyl)-
benzaldehyde (9b; 69 mg, 0.1 mmol), N-methylglycine (89 mg, 1.0
mmol), and C60 (144 mg, 0.2 mmol) in deaerated, anhydrous toluene
(200 mL) was stirred at 120 °C for 24 h under a nitrogen atmosphere.
After the mixture was cooled to room temperature, the solvent was
evaporated. The crude product was purified by column chromatog-
raphy (neutral alumina, n-hexane/toluene 3/1 then toluene) to yield a
3
(300 MHz, CD3CN, ppm): δ 8.96 (s, 2H, HD3), 8.75 (d, J = 8.2 Hz,
2H, HB3), 8.59 (d, 3J = 7.3 Hz, 2H, 2H, HC3), 8.49 (d, 3J = 8.3 Hz, 2H,
3
3
HA3), 8.41 (t, J = 8.1 Hz, 1H, HB4), 8.35 (d, J = 5.8 Hz, 2H, HG2),
8.21 (d, 3J = 7.5 Hz, 2H, HE2), 7.99−7.78 (m, 7H, HE3, HF6, HC4, HA4),
7.56−7.39 (m, 3H, HG3, HG4), 7.39 (d, 3J = 5.2 Hz, 2H, HA6), 7.34 (d,
3J = 5.3 Hz, 2H, HC6), 7.25 (s, 1H, HF3), 7.21−7.07 (m, 4H, HC5, HA5),
4.29−4.10 (m, 3H, α-OCH2), 4.08−3.92 (m, 1H, α-OCH2), 1.85−
1.59 (m, 4H, β-CH2), 1.55−1.02 (m, 20H, γ-η-CH2), 0.91−0.67 (m,
6H, CH3). HRMS (ESI-TOF, m/z): 904.2109, C127H66N6O2Ru ([M
− 2PF6]2+) requires 904.2143.
[Ru2(tpy)2(8c)](PF6)4 (1c). According to the general procedure for
heteroleptic ruthenium bis(terpyridine) complexes, [Ru(tpy)-
(MeCN)3](PF6)2 (9.7 mg, 13 μmol) and 8c (8.7 mg, 6.5 μmol)
were reacted to yield a dark red solid (8 mg, 3.1 μmol, 48%). 1H NMR
1
dark brown-black solid (101 mg, 0.07 mmol, 70%). Mp: 155 °C. H
NMR (400 MHz, CD2Cl2, ppm): δ 8.77 (s, 2H, HD3), 8.71 (d, 3J = 4.7
Hz, 2H, HC6), 8.68 (d, 3J = 7.9 Hz, 2H, HC3), 7.93−7.86 (m, 4H, HE2,
HC4), 7.67 (d, 3J = 8.5 Hz, 2H, HE3), 7.65 (s, 1H, HF5), 7.37 (ddd, 3J =
7.4 Hz, 3J = 4.8 Hz, 4J = 1.1 Hz, 2H, HC5), 7.09 (s, 1H, HF2), 5.58 (s,
3
(300 MHz, CD3CN, ppm): δ 9.08 (s, 4H, HD3), 8.80 (d, J = 8.1 Hz,
3
3
4H, HE2), 8.75 (d, J = 8.2 Hz, 4H, HB3), 8.67 (d, J = 7.9 Hz, 4H,
HC3), 8.54−8.37 (m, 10H, HA3, HE3, HB4), 8.00−7.86 (m, 8H, HC4,
2
2
1H, HH2), 4.97 (d, J = 9.4 Hz, 1H, HH5), 4.33 (d, J = 9.5 Hz, 1H,
H
HA4), 7.42 (d, J = 5.2 Hz, 4H, HA6), 7.36 (d, J = 5.2 Hz, 4H, HC6),
7.23−7.10 (m, 8H, HC5, HA5). 13C NMR (63 MHz, CD3CN, ppm): δ
159.07, 156.56, 156.33, 153.58, 153.32, 149.39, 148.32, 146.92, 146.27,
146.24, 145.74, 145.68, 145.46, 144.86, 144.05, 143.98, 143.15, 143.07,
141.96, 141.91, 139.13, 139.06, 138.81, 138.09, 136.89, 133.46, 129.54,
128.54, 128.49, 125.58, 125.47, 124.76, 122.76, 79.99, 58.28. HRMS
(ESI-TOF, m/z): 504.5643, C133H50N12Ru2 ([M − 4PF6]4+) requires
504.5599.
3
3
H5), 4.20 (dt, J = 9.5 Hz, J = 6.6 Hz, 1H, α-OCH2), 4.10 (dt, J =
2
3
2
9.6 Hz, 3J = 6.4 Hz, 1H, α-OCH2), 4.03 (dt, 2J = 13.1 Hz, 3J = 6.5 Hz,
2
3
1H, α-OCH2), 3.74 (dt, J = 8.6 Hz, J = 6.5 Hz, 1H, α-OCH2), 2.83
(s, 3H, NCH3), 1.87−1.76 (m, 2H, β-CH2), 1.73−1.49 (m, 6H, β-
CH2, γ-CH2), 1.48−1.17 (m, 16H, δ-η-CH2), 0.96−0.73 (m, 6H,
CH3). 13C NMR (100 MHz, CD2Cl2, ppm): δ 157.34, 156.51, 156.39,
155.57, 154.70, 154.68, 154.36, 152.03, 149.59, 149.58, 147.66, 147.22,
147.15, 146.62, 146.60, 146.56, 146.47, 146.43, 146.41, 146.32, 146.31,
146.14, 145.99, 145.90, 145.66, 145.64, 145.60, 145.58, 145.54, 145.48,
144.97, 144.92, 144.85, 144.72, 143.40, 143.36, 143.03, 142.99, 142.91,
142.74, 142.70, 142.62, 142.57, 142.50, 142.49, 142.47, 142.34, 142.19,
142.10, 142.08, 140.50, 140.45, 139.97, 139.91, 137.24, 136.83, 136.76,
136.54, 135.09, 132.45, 128.24, 127.65, 124.72, 124.34, 121.50, 118.88,
116.49, 115.24, 113.12, 93.52, 88.23, 77.05, 76.00, 70.33, 70.17, 69.77,
69.21, 40.24, 32.35, 32.32, 30.11, 29.93, 29.90, 29.82, 29.74, 29.73,
29.67, 26.55, 26.48, 23.19, 23.14, 21.55, 14.40, 14.35. MS (MALDI-
TOF, negative mode, terthiophene, m/z): 1440.42, C108H56N4O2 ([M
+ e]−) requires 1440.44. Anal. Calcd for C108H56N4O2·0.5(hexane): C,
89.79; H, 4.28; N, 3.77. Found: C, 89.78; H, 4.43; N, 3.83.
[Ru(tpy)(10a)](PF6)2 (2a). According to the general procedure for
heteroleptic ruthenium bis(terpyridine) complexes, [Ru(tpy)-
(MeCN)3](PF6)2 (8.9 mg, 12 μmol) and 10a (13 mg, 12 μmol)
were reacted to yield a dark red solid (7 mg, 4.1 μmol, 34%). 1H NMR
3
(300 MHz, CD3CN, ppm): δ 9.00 (s, 2H, HD3), 8.74 (d, J = 8.2 Hz,
3
3
2H, HB3), 8.62 (d, J = 7.8 Hz, 2H, HC3), 8.48 (d, J = 8.1 Hz, 2H,
HA3), 8.40 (t, J = 8.5 Hz, 1H, HB4), 8.34−8.19 (m, 4H, HE2, HE3),
3
7.98−7.86 (m, 4H, HC4, HA4), 7.40 (d, 3J = 5.5 Hz, 2H, HA6), 7.32 (d,
3J = 5.1 Hz, 2H, HC6), 7.21−7.08 (m, 4H, HC5, HA5), 5.29 (s, 1H,
2
2
H
H2), 5.14 (d, J = 9.5 Hz, 1H, HH5), 4.44 (d, J = 9.7 Hz, 1H, HH5),
2.91 (s, 3H, NCH3). HRMS (ESI-TOF, m/z): 709.5853, C99H31N7Ru
([M − 2PF6]2+) requires 709.5839.
General Procedure for the Synthesis of Heteroleptic
Ruthenium Bis(terpyridine) Complexes. A microwave vial was
charged with [Ru(tpy)(MeCN)3](PF6)2 (1 equiv per terpyridine
group), terpyridine derivative (1 equiv), and DMF (3 mL). The vial
was capped, purged with nitrogen for 20 min, and heated through
microwave irradiation at 140 °C for 30 min. Subsequently, the solution
was cooled to room temperature and the product was precipitated by
addition of an aqueous ammonium hexafluorophosphate solution. The
solid was collected by filtration, washed thoroughly with water and
diethyl ether, and dissolved in acetonitrile. The solution was
concentrated and treated with diethyl ether vapor to slowly precipitate
the complex. When applicable, deviations from this general protocol
are given below.
[Ru(tpy)(10b)](PF6)2 (2b). According to the general procedure for
heteroleptic ruthenium bis(terpyridine) complexes, [Ru(tpy)-
(MeCN)3](PF6)2 (15.6 mg, 21 μmol) and 10b (30 mg, 21 μmol)
1
were reacted to yield a dark red solid (23 mg, 11 μmol, 54%). H
NMR (400 MHz, CD2Cl2, ppm): δ 8.83 (s, 2H, HD3), 8.69 (d, 3J = 8.1
Hz, 2H, HB3), 8.51 (d, 3J = 7.8 Hz, 2H, HC3), 8.48−8.36 (m, 3H, HB4,
3
HA3), 8.12 (d, J = 8.0 Hz, 2H, HE2), 7.99−7.87 (m, 4H, HC4, HA4),
7.86 (d, 3J = 7.9 Hz, 2H, HE3), 7.69 (s, 1H, HF5), 7.39 (d, 3J = 5.4 Hz,
3
2H, HA6), 7.32 (d, J = 5.7 Hz, 2H, HC6), 7.26−7.17 (m, 4H, HC5,
2
HA5), 7.14 (s, 1H, HF2), 5.61 (s, 1H, HH2), 5.01 (d, J = 9.6 Hz, 1H,
2
H
H5), 4.37 (d, J = 9.4 Hz, 1H, HH5), 4.28−4.18 (m, 1H, α-OCH2),
4.18−4.09 (m, 1H, α-OCH2), 4.10−4.00 (m, 1H, α-OCH2), 3.82−
3.71 (m, 1H, α-OCH2), 2.86 (s, 3H, NCH3), 1.90−1.78 (m, 2H, β-
CH2), 1.73−1.12 (m, 22H, β-CH2, γ-η-CH2), 0.94−0.75 (m, 6H,
CH3). 13C NMR (100 MHz, DMSO-d6, ppm): δ 157.91, 157.74,
[Ru(tpy)(8a)](PF6)2 (1a). According to the general procedure for
heteroleptic ruthenium bis(terpyridine) complexes, [Ru(tpy)-
K
Inorg. Chem. XXXX, XXX, XXX−XXX